Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a severe respiratory illness resulted in widespread human infections and deaths in nearly all of the countries since late 2019. There is no therapeutic FDA-approved drug against SARS-CoV-2 infection, although a combination of anti-viral drugs is directly being practiced in some countries. A broad-spectrum of antiviral...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to COVID-19 Clinical Research Studies
• Share to Influenza Virus Research Studies
• Share to SARS-CoV-2 and COVID-19 Research